NCT04882124 - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

CSJ117

CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.

DRUG

Placebo

Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device

Trial Locations (15)

2100

Novartis Investigative Site, Gödöllő

2660

Novartis Investigative Site, Balassagyarmat

4101

Novartis Investigative Site, South Brisbane

6722

Novartis Investigative Site, Szeged

28078

Novartis Investigative Site, Huntersville

28150

Novartis Investigative Site, Shelby

36420

Novartis Investigative Site, Andalusia

63141

Novartis Investigative Site, St Louis

63301

Novartis Investigative Site, Saint Charles

70115

Novartis Investigative Site, New Orleans

70526

Novartis Investigative Site, Crowley

G1V 4G5

Novartis Investigative Site, Sainte-Foy

708 68

Novartis Investigative Site, Ostrava Poruba

457-8511

Novartis Investigative Site, Nagoya

319-1113

Novartis Investigative Site, Naka-gun